



A Forward-Looking Innovator in the Science of Caring

LINKING INNOVATION AND HUMANITY

At Kedrion Biopharma, we believe that every scientific innovation is meaningful only when it touches a life. By uniting innovation with humanity, we transform hope into health, one connection at a time. Our purpose is to unite the generosity of donors, the rigor of science, and the needs of patients, creating a global chain of care that changes lives every day.

The Power of Rare Connections

Kedrion Biopharma is a global biopharmaceutical company committed to improving the lives of people affected by rare, ultra-rare, and serious diseases. We operate worldwide, collecting and fractionating plasma to develop and distribute plasma-derived therapies that help prevent and manage debilitating conditions, including coagulation and neurological disorders, immunodeficiencies, and Rh sensitization.

Our global presence - supported by a broad product portfolio, an integrated manufacturing network, and a dedicated plasma collection infrastructure - demonstrates our ability to meet the needs of complex and constantly evolving markets.



PLASMA: A UNIQUE AND IRREPLACEABLE RESOURCE

Plasma is a vital component of blood and a limited resource that cannot be synthetically reproduced. Its availability depends entirely on donors.

FROM DONATION TO TREATMENT

Transforming plasma into therapies is a long and highly complex process that can take between **8 and 12 months**, involving rigorous quality controls and advanced scientific expertise.

THE CHAIN OF CARE

Every plasma donation is the first step in a global chain of care. From donors to scientists, from production to patients, each connection plays a crucial role in ensuring that therapies reach those who need them most.

KEY FACTS

-  HQs in Italy with subsidiaries in Europe, UK, North America, Latin America and Asia
-  5th world player in the field of plasma-derived products*
-  2025 turnover: 1.65 billion Euro
-  5,400+ people worldwide
-  67 plasma collection centers in the USA, 8 in the Czech Republic engaging approximately 200,000 donors
-  3 million liters of plasma collected
-  7 manufacturing plants in 5 countries
-  39 products
-  600+ marketing authorizations
-  Commercial presence in 100+ countries

* Source: Marketing Research Bureau "The Worldwide Plasma Protein Market 2024" and publicly available information




Supporting Rare Lives

Kedrion is driven by a unique approach that values every connection with donors, patients, employees, and partners. These relationships form the foundation of our work and inspire our commitment to delivering therapies that truly make an impact on people’s lives.

Every therapy we produce, every scientific investment we pursue, and every partnership we cultivate is rooted in our dedication to rare lives, individuals and families who rely on timely, effective, and compassionate care. Our Values guide us, ensuring that science remains human and every connection brings us closer to transforming hope into health.

OUR VALUES



Together
As One




Care



Integrity



Sustainable
Impact



Courage

RARE DISEASES: A GLOBAL CHALLENGE

Rare diseases affect millions of people worldwide. Today, an estimated 400 million people live with a rare disease, across 7,000–8,000* known conditions, most of which are chronic, severe, and often life-threatening.

Despite their individual rarity, rare diseases collectively represent a major global health challenge, calling for specialized knowledge, long-term commitment, and dedicated therapies.

*Source: Orphanet



66

We exist to connect the generosity of donors, the rigor of science, and the needs of patients, creating a global chain of care.



Science Serving Life

At Kedrion, science is at the heart of everything we do. Our commitment to research and innovation drives the development of new therapies and ensures continuous progress in patient care. We invest significantly in R&D, focusing on solutions for rare and ultra-rare diseases that still lack effective treatments.

Our partnerships with the medical and scientific community, institutions, patient advocacy groups, and research organizations enable us to drive sustainable innovation and improve patient outcomes. Every discovery is a new connection in the chain of hope, turning scientific advances into real-world impact for patients and families.

UNLOCKING NEW POSSIBILITIES



6 research projects focused on rare and ultra-rare diseases



Research on unused plasma processing intermediates

ADDRESSING UNMET MEDICAL NEEDS WITH ORPHAN THERAPIES

Kedrion is strongly committed to the development of orphan drugs for rare and ultra-rare conditions with limited or no available treatment options.

By focusing on unmet medical needs, we aim to provide new therapeutic solutions where they are needed most.

PLASMA-DERIVED THERAPIES FOR COMPLEX, RARE AND ULTRA-RARE CONDITIONS

Kedrion develops plasma-derived therapies that address serious, rare and ultra-rare diseases, including:

- Immunodeficiencies
- Coagulation disorders
- Neurological and autoimmune diseases
- Maternal-fetal protection, such as Rh sensitization

These therapies play a crucial role in restoring essential proteins and improving patients' quality of life.

Treating one patient with Hemophilia requires more than 1,200 plasma donations every year.

Treating a patient with Primary Immunodeficiency requires around 130 donations per year.



Connections that Transform Lives

Every Kedrion therapy begins with a generous act: plasma donation. Donors and their compassion create a chain of hope and healing that reaches patients around the world. Our work is to honor that gift transforming it through science into therapies.

We are deeply committed to expanding the availability of plasma-derived treatments, supporting local communities, and raising awareness of rare and ultra-rare diseases. Through education, collaboration, and sustainable growth, we ensure that every connection in our chain - donor, scientist, caregiver, patient - matters.

A LEGACY OF EXPERTISE

Across our integrated manufacturing plants, Kedrion brings together more than 100 years of experience in plasma fractionation.

This long-standing expertise supports our ability to transform a generous donation into safe, high-quality therapies, ensuring continuity of care for people in need.

WORKING TOGETHER FOR RARE LIVES

Progress in rare and ultra-rare diseases is only possible through collaboration. Kedrion works within a broad institutional ecosystem that includes:

- Donor associations
- Patient organizations
- Medical and scientific communities
- Institutional and healthcare stakeholders

By fostering strong partnerships, we help transform scientific knowledge into tangible benefits for patients and society.

66

Rare Connections
transform
generosity and
science into hope
for those who
need it most.



Learn more on www.kedrion.com

